![Andrew Neill](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Andrew Neill
Directeur Financier/CFO chez
SHATTUCK LABS, INC.
Fortune : 2 M $ au 30/06/2026
Profil
Andrew R.
Neill is the founder of Lumos Pharma, Inc., founded in 2010.
Mr. Neill currently works at Shattuck Labs, Inc. as Chief Financial Officer since 2021.
Mr. Neill attended Texas Christian University for undergraduate education.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
SHATTUCK LABS, INC. 0,32 % | 12/05/2026 | 292 251 ( 0,32 % ) | 2 M $ | 30/06/2026 |
Postes actifs de Andrew Neill
| Sociétés | Poste | Début |
|---|---|---|
| SHATTUCK LABS, INC. | Directeur Financier/CFO | 16/03/2021 |
Anciens postes connus de Andrew Neill
| Sociétés | Poste | Fin |
|---|---|---|
| LUMOS PHARMA, INC. | Fondateur | 01/08/2016 |
Formation de Andrew Neill
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
36
Relations au 1er degré
4
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 4 |
|---|---|
Texas Christian University
 Texas Christian University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Wharton School of the University of Pennsylvania
 The Wharton School of the University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Shattuck Labs, Inc.
 Shattuck Labs, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops therapeutics for inflammatory and immune-mediated diseases | Health Technology |
Lumos Pharma, Inc.
 Lumos Pharma, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and markets therapeutics for rare diseases | Health Technology |
